ERBB2 and breast carcinoma: The ZDHHC22 (abbreviated as ZDC22 in the Figures) expression was decreased in HER2-enriched and basal-like breast carcinoma, which had been verified as "more aggressive" subtypes, compared with luminal-like subtypes (Fig. 1B).